Replies to post #170 on The Medicines Company (MDCO)

[DewDiligence]

EGRX will launch liquid Angiomax product “at risk” as soon as it receives FDA approval:

#msg-118876127

Curious that MDCO never filed suit against EGRX under the standard Hatch-Waxman procedure.